Clinical Efficacy and Safety of Cd7-Targeted Car T Cell Therapy for T-Cell Malignancies: A Systematic Review and Meta-Analysis Publisher Pubmed



Dashti M¹ ; Habibi MA² ; Nejati N³ ; Robatjazi B⁴ ; Ahmadpour M⁵ ; Dokhani N⁶ ; Nejad AR⁷ ; Karami S⁸ ; Alinejad E⁹ ; Malekijoo AH¹⁰ ; Ghasemzadeh A¹ ; Jadidiniaragh F^{1, 11}
Source: Anti-cancer agents in medicinal chemistry Published:2025

Abstract

OBJECTIVES: Although T-cell malignancies are relatively less prevalent compared to B-cell malignancies, they are highly malignant, and patients usually have poor prognoses. Employing CD7-targeted chimeric antigen receptor (CAR) T cell therapy as a novel immunotherapy to treat malignant T cells faces numerous challenges and is in its early phase. To evaluate this possibility, we aimed to review and meta-analyze the related clinical trials systematically. METHODS: On October 9, 2023, the online databases of PubMed, Scopus, Embase, and Web of Science were systematically searched for pertinent studies. After completing a two-step title/abstract and full-text screening process, the eligible studies were included. RESULTS: We observed a pooled overall response rate (ORR) of 100%. Partial response (PR), stringent and/or complete response (sCR/CR), and relapse rate were 6%, 85%, and 18%, respectively. Additionally, the pooled rate of minimal residual disease (MRD) negativity was 85%. The most common grade ≥3 adverse events were related to hematological toxicities, including neutropenia (100%), thrombocytopenia (79%), and anemia (57%). Cytokine release syndrome (CRS) was also a frequent complication with a 100% rate; however, 81% of CRS events were low grades. No grade ≥3 GVHD was reported, and the immune effector cell-associated neurotoxicity syndrome (ICANS grade ≥3) was rare (4%). CONCLUSION: CD7 is an active and safe target that shows promising results in the treatment of relapsed and/or refractory (r/r) T-cell malignancies. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.